Health Care Equipment

VENUS MEDTECH-B

Qiming Medical Annual Revenue Down, Loss Narrowed

VENUS MEDTECH-B released FY2025 Q3 earnings on March 31 (BJT), actual revenue HKD 65.4 M, actual EPS HKD -0.3406

VENUS MEDTECH-B released FY2025 9 Months Earnings on March 31 (BJT), actual revenue HKD 268.02 M, actual EPS HKD -0.6731

VENUS MEDTECH-B released FY2025 Q4 earnings on March 31 During-Market (BJT), actual revenue HKD 66.53 M, actual EPS HKD -0.3465

VENUS MEDTECH-B released FY2025 earnings on March 31 During-Market (BJT), actual revenue HKD 335.3 M (forecast HKD 805.11 M), actual EPS HKD -1.0175 (forecast HKD -0.8151)

VENUS MEDTECH-B to Release FY2025 Earnings on March 31 During-Market (BJT), Forecast Revenue HKD 790.53 M, EPS HKD -0.8003

Qiming Medical-B Submits Cardiovalve System CE MDR Certification Application Documents

Qiming Medical-B Announces Mid-Term Clinical Results of Cardiovalve System TARGET Study

VENUS MEDTECH-B released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 100.21 M, actual EPS HKD -0.1648

VENUS MEDTECH-B released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), actual revenue HKD 202.62 M (forecast HKD 309.72 M), actual EPS HKD -0.3332 (forecast HKD -0.3763)

VENUS MEDTECH-B released FY2025 Q2 earnings on August 28 After-Market BJT, actual revenue HKD 102.41 M, actual EPS HKD -0.1684

VENUS MEDTECH-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT), Forecast Revenue HKD 309.72 M, EPS HKD -0.3763

Qiming Medical-B Elects Philip Wai-Hung Woo as New Chairman

Qiming Medical Announces 2024 Annual Report, Overseas Revenue Up 13.5%

Qiming Medical Reports Revenue and Net Profit Decline in 2024 Earnings

Qiming Medical-B's stock price rises over 8%, 2024 revenue forecast of 471 million RMB

VENUS MEDTECH-B released FY2024 Q3 earnings on March 28 (BJT), actual revenue 133.08 M HKD, actual EPS -0.6427 HKD

VENUS MEDTECH-B released FY2024 9 Months Earnings on March 28 (BJT), with actual revenue of 382.06 M HKD and EPS of -1.1515 HKD

Qiming Medical-B Releases 2024 Annual Performance, Focusing on Clinical Progress in Heart Disease

VENUS MEDTECH-B released FY2024 annual earnings on March 28 After-Market (BJT), actual revenue 509.66 M HKD (forecast 610.33 M HKD), actual EPS -1.7657 HKD (forecast -1.0859 HKD)

NTES-S

KWAN YONG

PEIJIA-B

REMEGEN

RADIANCE HLDGS

POP MART

BAOZUN-W

ARCHOSAUR GAMES

XIAOCAIYUAN

HEPALINK

02500

Venus Medtech (Hangzhou) Inc. has detailed its board composition, emphasizing independent oversight in governance. The board includes executive, non-executive, and independent non-executive directors, with independent directors chairing key committees. This structure aims to enhance corporate governance and reassure investors about oversight mechanisms. Venus Medtech is a medical technology company listed in Hong Kong under stock code 2500, focusing on innovative medical devices.

Tip Ranks

Venus Medtech Outlines Board and Committee Roles to Strengthen Governance

VENUS MEDTECH announced its full-year results for the year ended December last year, with a revenue of RMB 307 million, a year-on-year decrease of 34.8%. The loss narrowed to RMB 408 million, compared to a loss of RMB 714 million in the same period last year; the loss per share was RMB 0.93. No dividend was declared

AASTOCKS

"Performance" VENUS MEDTECH's annual loss narrowed to 408 million RMB, no dividend declared

516930

516500

562600

159898

159837

159883

159849

Venus Medtech Schedules Board Meeting to Approve 2025 Annual Results

Minsheng Royal CSI Biotechnology Theme ETF

First Trust NYSE Arca Biotech Index Fd

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC CSI All Share Health Care Devices ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

E Fund CSI Biotechnology Theme ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

China Merchants CSI Biotechnology Theme ETF

Venus Medtech Schedules Board Meeting to Approve 2025 Annual Results

02216

VENUS MEDTECH-B announced the sale of approximately 1.05% equity in the invested company Valgen Holding to an independent third party, for a cash consideration of USD 15 million, with estimated pre-tax gains from the sale of about USD 800,000. Upon completion, the company will no longer hold any shares in Valgen Holding

BRONCUS-B

VENUS MEDTECH sells minority investment, realizing USD 15 million

Cardiovalve, a subsidiary of Venus Medtech, has submitted technical documents for CE marking of its Transcatheter Tricuspid Valve Replacement (TTVR) system to DEKRA. This follows the successful TARGET study, which demonstrated the safety and efficacy of the Cardiovalve system in treating tricuspid regurgitation. The study involved 150 patients and showed promising results, leading to hopes for a new treatment option for TR patients. Cardiovalve aims for commercial launch by 2027.

prnewswire

12:31 ET
			
			
			
				
					Cardiovalve reicht nach erfolgreichem Abschluss der TARGET-Studie CE-Antrag zur Zulassung ein

Cardiovalve, a subsidiary of Venus Medtech, has submitted a CE technical file for its transcatheter tricuspid valve replacement system to DEKRA, following the successful TARGET study. The study demonstrated the safety and performance of the Cardiovalve system in treating tricuspid regurgitation, showing significant efficacy and a favorable safety profile. This submission marks a pivotal milestone towards CE certification and commercial rollout by 2027, offering a novel treatment option for patients with severe mitral and tricuspid regurgitation.

04:00 ET
			
			
				Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion

VENUS MEDTECH-B(02500.HK)

Venus Medtech Outlines Board and Committee Roles to Strengthen Governance

"Performance" VENUS MEDTECH's annual loss narrowed to 408 million RMB, no dividend declared

Venus Medtech Schedules Board Meeting to Approve 2025 Annual Results

VENUS MEDTECH sells minority investment, realizing USD 15 million

12:31 ET Cardiovalve reicht nach erfolgreichem Abschluss der TARGET-Studie CE-Antrag zur Zulassung ein

04:00 ET Cardiovalve Submits CE File for Approval Following Successful TARGET Study Completion